Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene

Oncotarget

Volumn 5, Issue 4, 2014, Pages 1052-1061

  Hoivik, Erling A ^a,b   Kusonmano, Kanthida ^a,b   Halle, Mari K ^a,b   Berg, Anna ^a,b   Wik, Elisabeth ^a,b   Werner, Henrica M J ^a   Petersen, Kjell ^b   Oyan, Anne M ^a,b   Kalland, Karl Henning ^a,b   Krakstad, Camilla ^a,b   Trovik, Jone ^a,b   Widschwendter, Martin ^c   Salvesen, Helga B ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

CTCF; CTCFL BORIS; Epi driver gene; Metastasis; Recurrence

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR CTCF; CTCFL PROTEIN, HUMAN; DNA BINDING PROTEIN; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; CTCFL GENE; DEMETHYLATION; DNA FINGERPRINTING; DNA METHYLATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; EPI DRIVER GENE; FEMALE; FRAMESHIFT MUTATION; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; HYPERPLASIA; METASTASIS; ONCOGENE; PRIMARY TUMOR; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE; BIOSYNTHESIS; DISEASE COURSE; ENDOMETRIUM TUMOR; GENETIC EPIGENESIS; GENETICS; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE;

AGED; CARCINOMA, ENDOMETRIOID; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA METHYLATION; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; EPIGENESIS, GENETIC; FEMALE; HUMANS; MUTATION; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 84897427195     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1697     Document Type: Article

References (44)

1. Di Cristofano A and Ellenson LH. Endometrial carcinoma. Annual review of pathology. 2007; 2:57-85.
2. Tao MH and Freudenheim JL. DNA methylation in endometrial cancer. Epigenetics: official journal of the DNA Methylation Society. 2010; 5(6):491-498.
3. Jones A, Teschendorff AE, Li Q, Hayward JD, Kannan A, Mould T, West J, Zikan M, Cibula D, Fiegl H, Lee SH, Wik E, Hadwin R, Arora R, Lemech C, Turunen H, et al. Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development. PLoS medicine. 2013; 10(11):e1001551.
4. Salvesen HB, Haldorsen IS and Trovik J. Markers for individualised therapy in endometrial carcinoma. The lancet oncology. 2012; 13(8):e353-361.
5. Fiorentino FP and Giordano A. The tumor suppressor role of CTCF. Journal of cellular physiology. 2012; 227(2):479-492.
6. Recillas-Targa F, de la Rosa-Velazquez IA and Soto-Reyes E. Insulation of tumor suppressor genes by the nuclear factor CTCF. Biochemistry and cell biology = Biochimie et biologie cellulaire. 2011; 89(5):479-488.
7. Lobanenkov VV, Nicolas RH, Adler VV, Paterson H, Klenova EM, Polotskaja AV and Goodwin GH. A novel sequence-specific DNA binding protein which interacts with three regularly spaced direct repeats of the CCCTC-motif in the 5'-flanking sequence of the chicken c-myc gene. Oncogene. 1990; 5(12):1743-1753.
8. Filippova GN, Fagerlie S, Klenova EM, Myers C, Dehner Y, Goodwin G, Neiman PE, Collins SJ and Lobanenkov VV. An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Molecular and cellular biology. 1996; 16(6):2802-2813.
9. Merkenschlager M and Odom DT. CTCF and cohesin: linking gene regulatory elements with their targets. Cell. 2013; 152(6):1285-1297.
10. Herold M, Bartkuhn M and Renkawitz R. CTCF: insights into insulator function during development. Development. 2012; 139(6):1045-1057.
11. Yang J and Corces VG. Chromatin insulators: a role in nuclear organization and gene expression. Advances in cancer research. 2011; 110:43-76.
12. Klenova EM, Morse HC, 3rd, Ohlsson R and Lobanenkov VV. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Seminars in cancer biology. 2002; 12(5):399-414.
13. Ohlsson R, Lobanenkov V and Klenova E. Does CTCF mediate between nuclear organization and gene expression? BioEssays: news and reviews in molecular, cellular and developmental biology. 2010; 32(1):37-50.
14. Pugacheva EM, Suzuki T, Pack SD, Kosaka-Suzuki N, Yoon J, Vostrov AA, Barsov E, Strunnikov AV, Morse HC, 3rd, Loukinov D and Lobanenkov V. The structural complexity of the human BORIS gene in gametogenesis and cancer. PloS one. 2010; 5(11):e13872.
15. Sleutels F, Soochit W, Bartkuhn M, Heath H, Dienstbach S, Bergmaier P, Franke V, Rosa-Garrido M, van de Nobelen S, Caesar L, van der Reijden M, Bryne JC, van Ijcken W, Grootegoed JA, Delgado MD, Lenhard B, et al. The male germ cell gene regulator CTCFL is functionally different from CTCF and binds CTCF-like consensus sites in a nucleosome composition-dependent manner. Epigenetics&chromatin. 2012; 5(1):8.
16. Kulkarni P, Shiraishi T, Rajagopalan K, Kim R, Mooney SM and Getzenberg RH. Cancer/testis antigens and urological malignancies. Nature reviews Urology. 2012; 9(7):386-396.
17. Simpson AJ, Caballero OL, Jungbluth A, Chen YT and Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nature reviews Cancer. 2005; 5(8):615-625.
18. Cancer Genome Atlas Research N, Genome Characterization C, Chang K, Creighton CJ, Davis C, Donehower L, Drummond J, Wheeler D, Ally A, Balasundaram M, Birol I, Butterfield YS, Chu A, Chuah E, Chun HJ, Dhalla N, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nature genetics. 2013; 45(10):1113-1120.
19. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MR and Futreal PA. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic acids research. 2011; 39(Database issue):D945-950.
20. Gregor A, Oti M, Kouwenhoven EN, Hoyer J, Sticht H, Ekici AB, Kjaergaard S, Rauch A, Stunnenberg HG, Uebe S, Vasileiou G, Reis A, Zhou H and Zweier C. De novo mutations in the genome organizer CTCF cause intellectual disability. American journal of human genetics. 2013; 93(1):124-131.
21. Zighelboim I, Mutch DG, Knapp A, Ding L, Xie M, Cohn DE and Goodfellow PJ. High Frequency Strand Slippage Mutations in CTCF in MSI-Positive Endometrial Cancers. Human mutation. 2013.
22. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N and Sander C. Emerging landscape of oncogenic signatures across human cancers. Nature genetics. 2013; 45(10):1127-1133.
23. Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, Price JC, Zhang S, England BM, Godwin AK, Sgroi DC, Program NIHISCCS, Hieter P, Mullikin JC, Merino MJ and Bell DW. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nature genetics. 2012; 44(12):1310-1315.
24. Goldman M, Craft B, Swatloski T, Ellrott K, Cline M, Diekhans M, Ma S, Wilks C, Stuart J, Haussler D and Zhu J. The UCSC Cancer Genomics Browser: update 2013. Nucleic acids research. 2013; 41(Database issue):D949-954.
25. Stavrum AK, Petersen K, Jonassen I and Dysvik B. Analysis of gene-expression data using J-Express. Current protocols in bioinformatics/editoral board, Andreas D Baxevanis [et al]. 2008; Chapter 7:Unit 7 3.
26. Chen K, Huang W, Huang B, Wei Y, Li B, Ge Y and Qin Y. BORIS, brother of the regulator of imprinted sites, is aberrantly expressed in hepatocellular carcinoma. Genetic testing and molecular biomarkers. 2013; 17(2):160-165.
27. Martin-Kleiner I. BORIS in human cancers -- a review. European journal of cancer. 2012; 48(6):929-935.
28. Renaud S, Pugacheva EM, Delgado MD, Braunschweig R, Abdullaev Z, Loukinov D, Benhattar J and Lobanenkov V. Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic acids research. 2007; 35(21):7372-7388.
29. Garraway LA and Lander ES. Lessons from the cancer genome. Cell. 2013; 153(1):17-37.
30. Rodriguez-Paredes M and Esteller M. Cancer epigenetics reaches mainstream oncology. Nature medicine. 2011; 17(3):330-339.
31. Wik E, Raeder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, Mjos S, Werner HM, Mannelqvist M, Stefansson IM, Oyan AM, Kalland KH, Akslen LA and Salvesen HB. Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(5):1094-1105.
32. Trovik J, Wik E, Werner HM, Krakstad C, Helland H, Vandenput I, Njolstad TS, Stefansson IM, Marcickiewicz J, Tingulstad S, Staff AC, MoMa TECsg, Amant F, Akslen LA and Salvesen HB. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. European journal of cancer. 2013; 49(16):3431-3441.
33. Cloke B and Christian M. The role of androgens and the androgen receptor in cycling endometrium. Molecular and cellular endocrinology. 2012; 358(2):166-175.
34. Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H, 3rd, Schrump DS, Risinger JI, Barrett JC and Lobanenkov VV. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer research. 2005; 65(17):7751-7762.
35. Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, et al. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer research. 2005; 65(17):7763-7774.
36. Renaud S, Loukinov D, Alberti L, Vostrov A, Kwon YW, Bosman FT, Lobanenkov V and Benhattar J. BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells. Nucleic acids research. 2011; 39(3):862-873.
37. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr. and Kinzler KW. Cancer genome landscapes. Science. 2013; 339(6127):1546-1558.
38. Tamborero D, Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Kandoth C, Reimand J, Lawrence MS, Getz G, Bader GD, Ding L and Lopez-Bigas N. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Scientific reports. 2013; 3:2650.
39. Gronbaek K, Hother C and Jones PA. Epigenetic changes in cancer. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica. 2007; 115(10):1039-1059.
40. Dawson MA and Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27.
41. Mkrtichyan M, Ghochikyan A, Davtyan H, Movsesyan N, Loukinov D, Lobanenkov V, Cribbs DH, Laust AK, Nelson EL and Agadjanyan MG. Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Cellular immunology. 2011; 270(2):188-197.
42. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(7):917-924.
43. Loukinov DI, Pugacheva E, Vatolin S, Pack SD, Moon H, Chernukhin I, Mannan P, Larsson E, Kanduri C, Vostrov AA, Cui H, Niemitz EL, Rasko JE, Docquier FM, Kistler M, Breen JJ, et al. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99(10):6806-6811.
44. Zhuang J, Jones A, Lee SH, Ng E, Fiegl H, Zikan M, Cibula D, Sargent A, Salvesen HB, Jacobs IJ, Kitchener HC, Teschendorff AE and Widschwendter M. The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS genetics. 2012; 8(2):e1002517.